Business Standard

Claris Lifesciences extends fall after board approves delisting proposal

The stock was down 3% to Rs 352, falling 6% from its early morning high of Rs 374 on the BSE.

Claris get nod for Tobramycin injection is the US
Premium

SI Reporter Mumbai
Claris Lifesciences was down 3% to Rs 352, falling 6% from its early morning high of Rs 374 on the BSE on Thursday, after the board of directors of the company approved the delisting proposal received from the promoter Athanas Enterprise Pvt Ltd. The stock ended 1% lower at Rs 362 on Wednesday.

"The promoter/promoter group of the company has made a voluntarily delisting offer representing 49.87% of the paid-up share capital of the company held by public shareholders," Claris Lifesciences said in a BSE filing.

During the board meeting held on December 6, 2017, the board also

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in